// App-Quantinova.ai

: Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC).

Researchers

Presenter

  • Arun Azad

Principal Investigators

  • Mark Voskoboynik

  • Ana Filipa Palma dos Reis

  • Anthony M. Joshua

  • Andrew James Weickhardt

  • Robert J. Jones

  • Pasquale Rescigno

  • Ben Tran

  • Caroline Kennedy

  • Spiros Linardopoulos

  • Ganesh Moorthy

  • TJ Zhou

  • Jessica S Brown

  • Edit Lukacs

  • Richard Francis

  • Andrew Hudson

Medical Centers

  • Olivia Newton-John Cancer Research Institute/ Austin Health, Heidelberg, Australia

  • Candiolo Cancer Institue - FPO, IRCCS, Turin, Italy

  • Addenbrookes Hospital, Cambridge, United Kingdom

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • AstraZeneca, Royston, United Kingdom

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

  • Institute of Cancer Science, University of Glasgow, Glasgow, United Kingdom

  • St. Vincent's Hospital, Sydney, Western Australia, Australia

  • AstraZeneca, Boston, MA

  • Alfred Health-Monash University, Melbourne, Australia

  • AstraZeneca, Waltham, MA

Locations

  • United States

  • Italy

  • United Kingdom

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Prostate cancer

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • 18F-fluorodeoxyglucose

  • Folate Hydrolase 1

  • Hormone receptor

  • Circulating DNA

Drug/Treatment

  • Adenosine

  • Adenosine Intravenous

  • Docetaxel

  • ribose

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Open Label

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT05367440

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved